Biogen reports two-year CELIA study findings supporting further development of diranersen

17/11/2026

On 17 November, the biotechnology company Biogen announced new results from its Phase II CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide therapy, in people with early Alzheimer’s disease (AD). The findings were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference in Boston, US.
CELIA is a global, randomised, double-blind and placebo-controlled Phase II study assessing the efficacy, safety and tolerability of diranersen. The trial enrolled 416 participants with mild cognitive impairment due to AD or mild AD dementia, none of whom had previously received anti-amyloid therapy.  Participants received one of three intrathecal dosing regimens: 60 mg every six months, 115 mg every six months or 115 mg every three months. The placebo-controlled treatment period lasted 18 months, followed by an ongoing open-label extension.
The primary endpoint was dose response in change from baseline in the Clinical Dementia Rating–Sum of Boxes (CDR-SB) score at Week 76. At two years (Week 96), the 60 mg twice-yearly regimen was associated with a 38% slowing of clinical decline on CDR-SB compared with the placebo-equivalent control group, corresponding to a 1.09-point treatment difference.
The two-year analysis also showed greater slowing of clinical decline across five of six measures compared with the 18-month results in the 60 mg dose group. These measures assessed cognition, daily functioning and disease progression. Clinical benefits were observed across all three dosing regimens, with the 60 mg twice-yearly regimen demonstrating the largest treatment effects at two years. Diranersen was generally well tolerated through two years, with no new safety signals reported.
According to Biogen, the findings support the continued development of diranersen and its further evaluation in a Phase III clinical trial designed to confirm its efficacy and safety. 
https://investors.biogen.com/news-releases/news-release-details/biogens-diranersen-demonstrates-increasing-clinical-benefit-two